摘要
目的:探讨二至丸治疗绝经后肝肾阴虚型骨质疏松症(postmenopausal osteoporosis,PMOP)的临床效果及对骨生化标志物的影响。方法:纳入诊断明确的肝肾阴虚PMOP患者96例,按照随机数字表法分为观察组和对照组,其中对照组48例采用阿仑膦酸钠片、碳酸钙D3片治疗,观察组48例在对照组治疗的基础上加用二至丸治疗,两组治疗周期均为6个月。观察比较两组临床疗效、骨密度(BMD)、血清骨代谢指标的变化。结果:观察组总有效率为93.75%,高于对照组的79.17%(P<0.05)。观察组治疗后第2~4腰椎(L2~4)、股骨颈骨密度(BMD)均高于对照组(P<0.05)。两组治疗后血清Ⅰ型前胶原氨基端肽(procollagen type Ⅰ N-peptide,PⅠNP)、Ⅰ型胶原羧基端肽β特殊序列(βisomer of the C-terminal telopeptide of typeⅠcollagen,β-CTX)、骨钙素(bone glaprotein,BGP)、骨碱性磷酸酶(bone alkaline phosphatase,BALP)均有下降趋势,且观察组均低于对照组,差异均有统计学意义(P<0.05)。结论:应用二至丸治疗肝肾阴虚POMP能增强骨密度,促进骨形成,抑制骨吸收,缓解改善相应症状体征,提高综合疗效。
Objective:To study the clinical effects and bone biochemical biomarkers of Erzhi Pills on live and kindney yin deficiency type of postmenopausal osteoporosis (PMOP).Method:A total of 96 diagnosed liver and kidney yin deficiency type of PMOP women were selected,they were divided into the observation group and the control group according to the random number table method,48 cases in each group.The control group was given Alendronate Sodium Tablets and Calcium Carbonate D3 Tablets,the observtion group was given Erzhi Pills on the basis of the control group,the treatment period of both two groups was 6 months.The clinical curative effects,bone mineral density (BMD),serum bone metabolism biomarkers of two groups were compared.Result:The total effective rate of the observation group was 93.75%,higher than 79.17% of the control group (P<0.05).After treatment,the BMD of L2-4 and femoral neck in the observation group were higher than those of the control group (P<0.05),Consistently,the serum concentrations of procollagen type Ⅰ N-peptide (PⅠNP),β isomer of the C-terminal telopeptide of typeⅠcollagen (β-CTX),bone gLaprotein (BGP) and bone alkaline phosphatase (BALP) were decreased in two groups after treatment,and these concentrations were significantly lower in the observation group than those of the control group (P<0.05).Conclusion:The application of Erzhi Pills to treat POMP of liver and kidney yin deficiency can enhance bone density,promote bone formation,inhibit bone absorption,relieve and improve the corresponding symptoms and signs,and improve the comprehensive efficacy.
作者
曾文泓
王丽华
梅鸥
ZENG Wenhong;WANG Lihua;MEI Ou(Jiangxi University of Traditional Chinese Medicine,Nanchang 330004,China;不详)
出处
《中国医学创新》
CAS
2020年第11期78-82,共5页
Medical Innovation of China
基金
江西省教育厅科技计划项目(GJJ160845)。
关键词
二至丸
绝经后骨质疏松症
骨生化标志
Erzhi Pills
Postmenopausal osteoporosis
Bone biochemical markers
